Ollin’s drug clears retinal disease better than Roche’s Vabysmo in Phase 1b trial

Just four months after its debut, Ollin Biosciences shared positive data from an early-stage study of its bispecific antibody for retinal diseases, and is already mapping out its registrational plans. Ollin’s drug, called OLN324, is ...